September 8, 2009 – Siemens Healthcare and SurgiVision Inc. today announced an agreement for the codevelopment and commercialization of a real-time magnetic resonance image (MRI)-guided cardiac electrophysiology (EP) system.

The HI-TORQUE Balance Middle Weight (BMW) Universal II Guide Wire offers the same performance of Abbott’s HT BMW UNIVERSAL wire, but includes the two advanced coating technologies and better coating durability for longer procedures

The Perclose ProGlide 6 Fr. Suture-Mediated Closure System delivers a secure, reliable vessel closure to provide complete tissue apposition resulting in primary healing, reduces time to hemostasis, ambulation and discharge, and does not have any reaccess restrictions.

September 3, 2009 – Percutaneous cardiac valve maker Evalve Inc. announced treatment this week of the first group of patients with the MitraClip system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

September 3, 2009 – Important new findings in patients with angina participating in the BEAUTIFUL study show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine), as presented today at the European Society of Cardiology (ESC) Congress.

September 3, 2009 – ZOLL Medical Corp. received approval from the FDA to market and sell a new model of the LifeVest wearable defibrillator.

The HI-TORQUE Versacore .035 Guide Wire is a peripheral guide wire is designed for routine diagnostic and device delivery for balloons and stents in peripheral vessels. Versacore features a soft, shapeable tip to provide safe access to peripheral lesions and enhanced visibility under fluoroscopy.

September 3, 2009 – On Tuesday, Aug. 11, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure.

The FoxCross PTA Catheter is a next-generation .035 balloon dilatation catheter is used to open peripheral arteries that have become blocked with plaque. The system is available in a wide variety of diameters (3-14 mm), balloon lengths (20-120 mm), and catheter lengths (50 cm, 80 cm and 135 cm) on an over-the-wire delivery platform.

September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now